Analysts say that all the attention being paid to the healthy effects of resveratrol [1] should boost Sirtris' efforts to push through an IPO it hopes will raise up to $60 million. Sirtris is focused on advancing sirtuin drugs to treat metabolic disorders like Type 2 diabetes and other age and diet-related diseases. But with only one drug in an early-stage trial, Cambridge, MA-based Sirtris is heading for the market at a much earlier stage than most biotechs would contemplate these days.

- here's the AP report [2] on the Sirtris IPO

Related Articles:
Sirtris pockets $37M in venture funds. Report [3]
Sirtris, Helicos file IPOs. Report [4]
Resveratrol may boost longevity, health. Report [5]